🔍

Norris Medicines Ltd (524414)

📊 BSE: 524414 🏢 Trading & Distributors 📢 Latest filing: 29 Sep 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Norris Medicines' revenue was ₹0.9 Cr (-36.7% year on year, -34.4% on the previous quarter), and net profit ₹-0.4 Cr (a bigger loss than a year earlier); the operating margin was -30.5%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹0.9	-36.7%	-34.4%
Operating profit	₹-0.3	loss widened	to loss
Net profit	₹-0.4	loss widened	to loss
EPS (₹)	-0.40	loss widened	to loss
Operating margin	-30.5%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Norris Medicines Shareholders Approve Borrowing Limit Hike and Asset Disposal Powers at 35th AGM

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 29 Sep 2026, 06:56 PM

Norris Medicines announced the voting results of its 35th Annual General Meeting held on September 29, 2026. All proposed resolutions were approved by shareholders with 99.59% majority among valid votes polled, representing 67.40% voter turnout. Key special resolutions passed include increasing borrowing limits, authorizing the sale, lease, or disposal of the company's undertaking, and raising investment limits under Section 186. The reappointment of Managing Director Vimal D. Shah was also approved, though his 2,360,441 interested votes were invalidated for that specific agenda item.

Overall voter turnout stood at 67.40% with 67,40,630 votes polled out of 1,00,00,700 total shares
Special resolution authorizing sale, lease, or disposal of the undertaking passed with 99.59% approval (67,12,970 votes in favour)
Resolution to increase company borrowing limits approved with 99.59% votes in favour and 27,660 votes (0.41%) against
23,60,441 promoter votes cast by MD Vimal D. Shah were marked invalid for his own re-appointment resolution due to conflict of interest

💡 Monitor upcoming board disclosures regarding any specific asset sales or debt restructuring moves initiated under the newly approved Section 180 and Section 186 authorizations.

Norris Medicines Appoints Vimal Dhirendra Shah as Managing Director for a 3-Year Term

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 14 Aug 2026, 05:34 PM

Norris Medicines Limited has approved the appointment of Mr. Vimal Dhirendra Shah as Managing Director (Promoter and Executive) for a term of 3 consecutive years, effective from September 01, 2026 to August 31, 2029. The appointment is subject to shareholder approval. Mr. Shah brings over 15 years of experience in business management. The leadership appointment comes as the company navigates a stressed balance sheet with a net worth of Rs -15 Cr and total debt of Rs 22 Cr on TTM revenue of Rs 8 Cr.

Appointed Mr. Vimal Dhirendra Shah as Managing Director for a 3-year term from September 01, 2026 to August 31, 2029
Appointee holds over 15 years of experience in business management and operations
The appointment was approved by the Board on August 14, 2026, and is subject to shareholder approval
Board meeting commenced at 03:00 PM and concluded at 04:00 PM on August 14, 2026

💡 Track the upcoming shareholder voting results for the ratification of the Managing Director appointment and monitor quarterly execution to gauge operational turnaround.

Norris Medicines Approves Q1 Results, Appoints Vimal D. Shah as MD for 3 Years

🟡 NEUTRAL ⭐ 5/10

MANAGEMENT 📅 14 Aug 2026, 05:26 PM

Norris Medicines' Board of Directors approved the un-audited financial results for the quarter ended June 30, 2026. The Board also approved the appointment of Mr. Vimal Dhirendra Shah as Managing Director (Promoter & Executive) for a 3-year term effective September 1, 2026, to August 31, 2029. The appointment is subject to approval by company shareholders. Mr. Shah holds over 15 years of experience in business management.

Appointed Mr. Vimal Dhirendra Shah as Managing Director for a 3-year term starting September 1, 2026.
Appointment is effective until August 31, 2029, and subject to shareholder approval.
Board approved un-audited financial results for the quarter ended June 30, 2026.
Appointee possesses over 15 years of experience in business management.

💡 Track the full Q1 FY27 financial table disclosures for operational turnaround metrics and monitor shareholder voting on the MD appointment.

Norris Medicines Appoints Vimal Dhirendra Shah as Managing Director for 3-Year Term

🟡 NEUTRAL ⭐ 5/10

MANAGEMENT 📅 14 Aug 2026, 05:18 PM

Norris Medicines Limited approved its un-audited financial results for the quarter ended June 30, 2026, at its board meeting on August 14, 2026. The Board also approved the appointment of Mr. Vimal Dhirendra Shah as Managing Director (Promoter & Executive) for a 3-year term from September 1, 2026, to August 31, 2029. The appointment is subject to shareholder approval and is liable to retire by rotation.

Appointment of Mr. Vimal Dhirendra Shah as Managing Director approved for a term of 3 consecutive years
Term effective from September 01, 2026 till August 31, 2029 (subject to shareholder approval)
Approved Un-Audited Financial Results for the quarter ended June 30, 2026
Board meeting commenced at 03:00 PM and concluded at 04:00 PM on August 14, 2026

💡 Investors should track the upcoming shareholder voting on the Managing Director appointment and review the detailed Q1 FY27 financial results filing to assess operational turnaround.

Norris Medicines Board Meeting on August 14, 2026, to Approve Q1 FY27 Results

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 08 Aug 2026, 02:56 PM

Norris Medicines Ltd has scheduled a board meeting for August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company is a micro-cap entity with a market capitalization of just ₹15 Cr and a significantly stressed balance sheet, featuring a negative net worth of ₹-15 Cr and debt of ₹22 Cr. The trading window for insiders has been closed since July 1, 2026, and will reopen 48 hours after the results are announced. Investors should focus on whether the company can maintain the marginal profitability achieved in the March 2026 quarter (₹0.05 Cr PAT).

Board meeting scheduled for August 14, 2026, to approve Q1 FY27 results.
Trading window closed from July 1, 2026, until 48 hours post-result declaration.
Company reported a TTM revenue of ₹8 Cr against a debt of ₹22 Cr.
Net worth remains negative at ₹-15 Cr as per latest available data.
Promoter holding has remained stable at approximately 34.01% as of March 2026.

💡 Monitor the upcoming financial results on August 14 for signs of operational stability, specifically looking for improvements in the Operating Profit Margin (TTM 8.1%) and debt reduction progress.

Norris Medicines Appoints Iqubal Ismail Patel as CFO and KMP

🟡 NEUTRAL ⭐ 7/10

MANAGEMENT 📅 30 Jul 2026, 06:26 PM

Norris Medicines has appointed Mr. Iqubal Ismail Patel as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) effective July 30, 2026. Mr. Patel is an internal promotee with over 11 years of experience at the company, specializing in finance, taxation, and budgeting. This leadership change occurs as the company manages a stressed balance sheet with a negative net worth of Rs -15 Cr and debt of Rs 22 Cr. Given the company's small scale (TTM revenue of Rs 8 Cr), the CFO's role in managing liquidity and debt will be critical.

Appointment of Mr. Iqubal Ismail Patel as CFO and KMP effective July 30, 2026
Mr. Patel has been associated with the company for more than 11 years
Company reports a negative net worth of Rs -15 Cr against a debt of Rs 22 Cr
TTM revenue stands at Rs 8 Cr with a market capitalization of only Rs 16 Cr

💡 Watch for the next quarterly results to see if the new CFO can implement strategies to address the negative net worth and high debt-to-revenue ratio.

Norris Medicines Appoints Iqubal Ismail Patel as CFO Effective July 30, 2026

🟡 NEUTRAL ⭐ 7/10

MANAGEMENT 📅 30 Jul 2026, 06:17 PM

Norris Medicines has appointed Mr. Iqubal Ismail Patel as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) effective July 30, 2026. Mr. Patel is an internal candidate with over 11 years of experience within the company across finance, taxation, and budgeting. This appointment is significant for a micro-cap company (Market Cap ₹16 Cr) currently facing financial stress, including a negative net worth of ₹-15 Cr and debt of ₹22 Cr. The internal promotion suggests a preference for continuity in managing the company's tight financial position.

Appointment of Mr. Iqubal Ismail Patel as CFO and KMP effective July 30, 2026
Mr. Patel has been associated with the company for more than 11 years
Company operates with a negative net worth of ₹-15 Cr as per latest financial context
Total debt stands at ₹22 Cr against a TTM revenue of ₹8 Cr
Board meeting for the appointment concluded within 30 minutes (5:00 PM to 5:30 PM)

💡 Watch for the new CFO's strategy regarding debt management and efforts to turn around the negative net worth position in upcoming quarterly results.

View All 524414 Announcements on Live Market Tracking →